Lacosamide Fresenius Kabi (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilises hyper‑excitable neurons and limits repetitive firing, thereby decreasing the likelihood of seizure propagation without markedly affecting normal rapid sodium channel activity.

The specific dosing regimen for Lacosamide Fresenius Kabi is determined by the prescribing clinician based on the patient’s clinical condition, age, renal function and concomitant therapies. Healthcare professionals should follow local prescribing guidelines and adjust the dose as needed.

Safety data for lacosamide in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Lacosamide differs from many traditional antiepileptics such as carbamazepine or phenytoin by selectively enhancing the slow inactivation of sodium channels, which may result in a distinct side‑effect profile and fewer drug‑enzyme interactions. Compared with levetiracetam, lacosamide offers an alternative mechanism for patients who do not achieve adequate control with other agents.

Lacosamide Fresenius Kabi should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature, it may be used within the time frame specified in the product label.

The medication is given by intravenous injection or infusion under the supervision of a qualified healthcare professional. The rate of administration and dilution instructions are provided in the prescribing information and should be followed to ensure safe and effective delivery.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation, which can lead to arrhythmias, as well as rare but severe skin reactions (e.g., Stevens‑Johnson syndrome) and the emergence of suicidal thoughts or behaviours. Prompt medical evaluation is required if any of these occur.

Lacosamide is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Patients with significant cardiac conduction disorders (e.g., second‑degree AV block) should avoid use unless closely monitored, as the medication can exacerbate PR‑interval prolongation.